EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Revolutionizing pharmaceutical innovation: Unveiling the impact of endogenous knowledge spillover in China

Zhuolin Li iD, Lin Guo iD, Ying Ping

PLOS ONE · 2024

DOI: 10.1371/journal.pone.0307171 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Zhuolin Li und 2 weiteren Autor:innen. Beteiligte Einrichtung: College of Economics and Management, Shanghai Ocean University, Shanghai, China. Hauptthemen laut MEDLINE: Drug Industry, Inventions. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Modern medical technology innovation is a critical safeguard for human health, while a significant number of developing nations are confronted with the challenge of biopharmaceutical technological advancement. To investigate the possible routes of technological advancement, we investigated the impact of the endogenous knowledge spillover effect on firm innovation endeavors. Our research involves a theoretical two-stage R&D game model that is built around the characteristics of pharmaceutical organizations. Theoretical studies elucidated the impact as well as the probable mechanism of the spillover effect. To verify the theoretical study, we conducted econometric analysis using data from the pharmaceutical sector of Chinese enterprise listed on the A-share market. The study’s findings indicate that endogenous knowledge spillovers impede organizations’ innovation endeavors. This phenomenon may be attributed to the existence of the patent race paradigm and high concentration of enterprises’ R&D endeavors in specific areas. Additional examination of heterogeneity demonstrates that private firms, small and medium-sized enterprises (SMEs), and non-high-tech enterprises experience a larger adverse impact from the spillover effect. Hence, we suggest implementing "loser’s subsidies", reallocating R&D resources, and making modifications to competition policies as measures to enhance the innovation performance of biopharmaceutical markets. These policies will facilitate the technical advancement of medicines in developing nations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug IndustryInventionsChinaHumansKnowledge

Autor:innen und Institutionen

  • College of Economics and Management, Shanghai Ocean University, Shanghai, China.

ORCID-Profile: Zhuolin Li, Lin Guo

Zitieren

APA

Li, Z., Guo, L., & Ping, Y. (2024). Revolutionizing pharmaceutical innovation: Unveiling the impact of endogenous knowledge spillover in China. PLOS ONE. https://doi.org/10.1371/journal.pone.0307171

Vancouver

Li Z, Guo L, Ping Y. Revolutionizing pharmaceutical innovation: Unveiling the impact of endogenous knowledge spillover in China. PLOS ONE. 2024. doi:10.1371/journal.pone.0307171

BibTeX
@article{Li2024,
  author = {Li, Zhuolin and Guo, Lin and Ping, Ying},
  title = {Revolutionizing pharmaceutical innovation: Unveiling the impact of endogenous knowledge spillover in China},
  journal = {PLOS ONE},
  year = {2024},
  doi = {10.1371/journal.pone.0307171}
}
Kostenlos starten →